Mocht u onze website waarderen, wij hebben een ANBI status , dus uw gift / donatie is aftrekbaar voor de inkomstenbelasting, dan wilt u misschien een gift / donatie overmaken naar onderstaand rekeningnummer met vermelding gift 2026. 

NL79 RABO 0372931138 t.n.v. Stichting Gezondheid Actueel in Terneuzen. BIC/SWIFTCODE RABONL2U. 

Zie ook in gerelateerde artikelen hiernaast of hieronder.

3 augustus 2026: Bron: Nature d.d. november 2025

Wanneer patiënten met de ziekte van Alzheimer - dementie gedurende korte sessies van 30 minuten per dag intermitterende hypercapnie – gecontroleerde blootstelling aan lage CO2-niveaus in aan-uit-cycli – krijgen toegediend via een zuurstofmasker dan blijkt het glymfatische systeem van de hersenen te worden geactiveerd.
Op die manier zorgen de CO2-pulsen ervoor dat bloedvaten in de hersenen verwijden en vernauwen, wat fungeert als een pomp die de vloeistofstroom door het hersenweefsel stimuleert. Daardoor worden giftige eiwitten zoals alfa-synucleïne, amyloïde bèta en gefosforyleerd tau die verband houden met de ziekte van Alzheimer - dementie en de ziekte van Parkinson afgevoerd. In feite worden de hersenen via deze korte pulsen van CO2 dus als het ware schoongemaakt. 

Het glymfatische systeem functioneert als de afvoerroute voor afvalstoffen in de hersenen. Het is het meest actief tijdens de diepe slaap en is vaak verstoord bij neurodegeneratieve aandoeningen. Onderzoekers gebruikten maskers die afwisselend pulsen CO2-verrijkte lucht aan de deelnemers gaven. Ze observeerden een verbeterde verwijdering van gefosforyleerd tau uit de hersenen en verhoogde niveaus van amyloïde bèta in de bloedbaan, wat erop wijst dat de eiwitten werden afgevoerd. "Deze verwijding en vernauwing werkt in feite als een pomp die afvalstoffen uit de hersenen verwijdert", aldus prof. dr. Ryman, hoofd van het onderzoeksteam in de berichtgeving over de presentatie.

De studiepresentatie van afgelopen maand heb ik nog niet kunnen vinden maar wel de publicatie in Nature die gratis is in te zien of te downloaden. Ik vermoed dat het dezelfde studie is. 

The influence of intermittent hypercapnia on cerebrospinal fluid flow and clearance in Parkinson’s disease and healthy older adults

npj Parkinson's Disease volume 11, Article number: 334 (2025) Cite this article


Abstract

A failure of the glymphatic pathway to clear brain byproducts implicated in neurodegeneration may contribute to the pathophysiology of Parkinson’s disease. The glymphatic pathway relies on vasomotion (rhythmic constriction and dilation of blood vessels) to drive cerebrospinal fluid through the interstitial space and clear waste from the brain. The current study demonstrated that intermittent hypercapnia, exposure to low levels of CO2 in ON-OFF cycles, elicited vasomotion-induced cerebrospinal fluid inflow in both healthy controls and individuals with Parkinson’s disease. The magnitude of the vasomotion-induced cerebrospinal fluid inflow in patients with Parkinson’s disease was reduced relative to healthy controls. However, intermittent hypercapnia, administered in three 10-minute sessions totaling approximately 30 minutes, increased the appearance of total α-synuclein, neurofilament light, glial fibrillary acidic protein, amyloid β1-42, amyloid β1-40, and phosphorylated tau 217 in the plasma of both healthy controls and individuals with Parkinson’s disease. This suggests that intermittent hypercapnia can be used to clear potentially toxic brain byproducts from the brain, highlighting its potential use as a disease modifying treatment.

Referenties:

  1. Coughlin, D. G., Hurtig, H. I. & Irwin, D. J. Pathological influences on clinical heterogeneity in Lewy body diseases. Mov. Disord. 35, 5–19 (2020).

    Article PubMed Google Scholar 

  2. Hirsch, E. C. & Hunot, S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection?. Lancet Neurol. 8, 382–397 (2009).

    Article CAS PubMed Google Scholar 

  3. Calabresi, P. et al. Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 14, 176 (2023).

    Article PubMed PubMed Central Google Scholar 

  4. Massey, A. et al. Glymphatic System Dysfunction and Sleep Disturbance May contribute to the pathogenesis and progression of Parkinson’s Disease. Int. J. Mol. Sci. 23, 12928 (2022).

    Article Google Scholar 

  5. Sundaram, S. et al. Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson’s disease. Neurosci. Biobehav. Rev. 103, 305–315 (2019).

    Article CAS PubMed PubMed Central Google Scholar 

  6. Ryman, S. G. et al. Abnormal cerebrovascular activity, perfusion and glymphatic clearance in Lewy body diseases. Mov. Disord. 39, 1258–1268 (2024).

    Article CAS PubMed PubMed Central Google Scholar 

  7. Iliff, J. J. et al. Cerebral arterial pulsation drives paravascular CSF–interstitial fluid exchange in the murine brain. J. Neurosci. 33, 18190–18199 (2013).

    Article CAS PubMed PubMed Central Google Scholar 

  8. Goodman, J. R. & Iliff, J. J. Vasomotor influences on glymphatic-lymphatic coupling and solute trafficking in the central nervous system. J. Cereb. Blood Flow. Metab. 40, 1724–1734 (2020).

    Article CAS PubMed Google Scholar 

  9. Cui, H. et al. Decreased AQP4 expression aggravates ɑ-synuclein pathology in Parkinson’s disease mice, possibly via impaired glymphatic clearance. J. Mol. Neurosci. 71, 1–14 (2021).

    Article Google Scholar 

  10. Zhang, Y. et al. Interaction between the glymphatic system and α-synuclein in Parkinson’s disease. Mol. Neurobiol. 60, 2209–2222 (2023).

    Article CAS PubMed Google Scholar 

  11. Shen, T. et al. The role of brain perivascular space burden in early-stage Parkinson’s disease. NPJ Parkinson’s Dis. 7, 12 (2021).

    Article CAS Google Scholar 

  12. He, P. et al. The Association of the glymphatic function with Parkinson’s disease symptoms: neuroimaging evidence from longitudinal and cross-sectional studies. Ann. Neurol. 94, 672–683 (2023).

    Article PubMed Google Scholar 

  13. Lee, D. A., Lee, H. & Park, K. M. Glymphatic dysfunction in isolated REM sleep behavior disorder. Acta Neurol. Scand. 145, 464–470 (2022).

    Article PubMed Google Scholar 

  14. Bae, Y. J. et al. Altered brain glymphatic flow at diffusion-tensor MRI in rapid eye movement sleep behavior disorder. Radiology 307, e221848 (2023).

    Article PubMed Google Scholar 

  15. Park, Y. W. et al. Magnetic resonance imaging–visible perivascular spaces in basal ganglia predict cognitive decline in Parkinson’s disease. Mov. Disord. 34, 1672–1679 (2019).

    Article PubMed Google Scholar 

  16. Wood, K. H. et al. Diffusion tensor imaging-along the perivascular-space index is associated with disease progression in Parkinson’s disease. Mov. Disord. 39, 1504–1513 (2024).

    Article PubMed PubMed Central Google Scholar 

  17. Lin, C.-H. et al. Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology 93, e1104–e1111 (2019).

    Article CAS PubMed Google Scholar 

  18. Aamodt, W. W. et al. Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease. Mov. Disord. 36, 2945–2950 (2021).

    Article CAS PubMed PubMed Central Google Scholar 

  19. Pilotto, A. et al. Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease. J. Neurol. 271, 7537–7546 (2024).

    Article CAS PubMed PubMed Central Google Scholar 

  20. Batzu, L. et al. Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease. npj Parkinson’s Dis. 8, 154 (2022).

    Article CAS Google Scholar 

  21. Chen, N.-C. et al. Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease. Front. Aging Neurosci. 12, 112 (2020).

    Article CAS PubMed PubMed Central Google Scholar 

  22. Benveniste, H. et al. The glymphatic system and waste clearance with brain aging: a review. Gerontology 65, 106–119 (2019).

    Article PubMed Google Scholar 

  23. van Veluw, S. J. et al. Vasomotion as a driving force for paravascular clearance in the awake mouse brain. Neuron 105, 549–561 (2020).

    Article PubMed Google Scholar 

  24. Hauglund, N. L. et al. Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep. Cell 188, 606–622 (2025).

    Article CAS PubMed Google Scholar 

  25. Mestre, H. et al. Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension. Nat. Commun. 9, 4878 (2018).

    Article PubMed PubMed Central Google Scholar 

  26. Helakari, H. et al. Human NREM sleep promotes brain-wide vasomotor and respiratory pulsations. J. Neurosci. 42, 2503–2515 (2022).

    Article CAS PubMed PubMed Central Google Scholar 

  27. Murdock, M. H. et al. Multisensory gamma stimulation promotes glymphatic clearance of amyloid. Nature 627, 149–156 (2024).

    Article CAS PubMed PubMed Central Google Scholar 

  28. Holstein-Rønsbo, S. et al. Glymphatic influx and clearance are accelerated by neurovascular coupling. Nat. Neurosci. 1, 12 (2023).

    Google Scholar 

  29. Ryman, S. G. et al. Reduced and Delayed Cerebrovascular Reactivity in Patients with Parkinson’s Disease. Mov. Disord. 38, 1260–1272 (2023).

    Article Google Scholar 

  30. van der Horn, H. J. et al. Parkinson’s disease cerebrovascular reactivity pattern: a feasibility study. J. Cerebral Blood Flow Metab. 44, 1774–1786 (2024).

    Article CAS Google Scholar 

  31. Fultz, N. E. et al. Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep. Science 366, 628–631 (2019).

    Article CAS PubMed PubMed Central Google Scholar 

  32. Yang, H.-C. et al. Coupling between cerebrovascular oscillations and CSF flow fluctuations during wakefulness: an fMRI study. J. Cereb. Blood Flow. Metab. 42, 1091–1103 (2022).

    Article PubMed PubMed Central Google Scholar 

  33. Nair, V. V. et al. Neurofluid coupling during sleep and wake states. Sleep. Med. 110, 44–53 (2023).

    Article PubMed Central Google Scholar 

  34. Han, F. et al. Decoupling of global brain activity and cerebrospinal fluid flow in Parkinson’s disease cognitive decline. Mov. Disord. 36, 2066–2076 (2021).

    Article CAS PubMed PubMed Central Google Scholar 

  35. Wang, Z. et al. Reduced coupling of global brain function and cerebrospinal fluid dynamics in Parkinson’s disease. J. Cereb. Blood Flow Metab. 43, 1328–1339 (2023).

    Article CAS PubMed PubMed Central Google Scholar 

  36. Wang, Y. et al. Cerebrovascular activity is a major factor in the cerebrospinal fluid flow dynamics. Neuroimage 258, 119362 (2022).

    Article PubMed Google Scholar 

  37. van der Voort, E. C et al. CO2 as an engine for neurofluid flow: Exploring the coupling between vascular reactivity, brain clearance, and changes in tissue properties. NMR Biomed. 37, e5126 (2024).

  38. Carr, J. M., Caldwell, H. G. & Ainslie, P. N. Cerebral blood flow, cerebrovascular reactivity and their influence on ventilatory sensitivity. Exp. Physiol. 106, 1425–1448 (2021).

    Article PubMed Google Scholar 

  39. Hoiland, R. L., Fisher, J. A. & Ainslie, P. N. Regulation of the cerebral circulation by arterial carbon dioxide. Compr. Physiol. 9, 1101–1154 (2019).

    Article PubMed Google Scholar 

  40. van Der Voort, E. C. et al. CO2 as an engine for neurofluid flow: Exploring the coupling between vascular reactivity, brain clearance, and changes in tissue properties. NMR Biomed. 37, e5126 (2024).

    Article PubMed PubMed Central Google Scholar 

  41. Della Monica, C. et al. P-tau217 and other blood biomarkers of dementia: variation with time of day. Transl. Psychiatry 14, 373 (2024).

    Article PubMed PubMed Central Google Scholar 

  42. Iliff, J. J. et al. The glymphatic system clears amyloid beta and tau from brain to plasma in humans. medRxiv 2024–07 (2024).

  43. Eide, P. K. et al. Plasma neurodegeneration biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological disorders. Nat. Commun. 14, 2084 (2023).

    Article CAS PubMed PubMed Central Google Scholar 

  44. Zheng, X., Yang, J., Hou, Y., Shi, X. & Liu, K. Prediction of clinical progression in nervous system diseases: plasma glial fibrillary acidic protein (GFAP). Eur. J. Med. Res. 29, 51 (2024).

    Article CAS PubMed PubMed Central Google Scholar 

  45. Gafson, A. R. et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain 143, 1975–1998 (2020).

    Article PubMed PubMed Central Google Scholar 

  46. Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using lme4. J. Stat. Softw. 67, 1–48 (2015).

    Article Google Scholar 

  47. Bhavani-Shankar, K., Moseley, H., Kumar, A. & Delph, Y. Capnometry and anaesthesia. Can. J. Anaesth. 39, 617–632 (1992).

    Article CAS PubMed Google Scholar 

  48. Buongiorno, M. et al. Altered sleep and neurovascular dysfunction in alpha-synucleinopathies: the perfect storm for glymphatic failure. Front. Aging Neurosci. 15, 1251755 (2023).

    Article CAS PubMed PubMed Central Google Scholar 

  49. Koep, J. L. et al. Autonomic control of cerebral blood flow: fundamental comparisons between peripheral and cerebrovascular circulations in humans. J. Physiol. 600, 15–39 (2022).

    Article CAS PubMed Google Scholar 

  50. Lohela, T. J., Lilius, T. O. & Nedergaard, M. The glymphatic system: implications for drugs for central nervous system diseases. Nat. Rev. Drug Discov. 21, 763–779 (2022).

    Article CAS PubMed Google Scholar 

  51. Lee, H. et al. The effect of body posture on brain glymphatic transport. J. Neurosci. 35, 11034–11044 (2015).

    Article CAS PubMed PubMed Central Google Scholar 

  52. von Holstein-Rathlou, S., Petersen, N. C. & Nedergaard, M. Voluntary running enhances glymphatic influx in awake behaving, young mice. Neurosci. Lett. 662, 253–258 (2018).

    Article Google Scholar 

  53. He, X. et al. Voluntary exercise promotes glymphatic clearance of amyloid beta and reduces the activation of astrocytes and microglia in aged mice. Front. Mol. Neurosci. 10, 144 (2017).

    Article PubMed PubMed Central Google Scholar 

  54. Liu, X. et al. Polyunsaturated fatty acid supplement alleviates depression-incident cognitive dysfunction by protecting the cerebrovascular and glymphatic systems. Brain, Behav. Immun. 89, 357–370 (2020).

    Article CAS PubMed Google Scholar 

  55. Ren, H. et al. Omega-3 polyunsaturated fatty acids promote amyloid-β clearance from the brain through mediating the function of the glymphatic system. FASEB J. 31, 282–293 (2017).

    Article CAS PubMed Google Scholar 

  56. van Hattem, T. et al. Targeting sleep physiology to modulate glymphatic brain clearance. Physiology 40, 271–290 (2025).

    Article Google Scholar 

  57. Xie, L. et al. Sleep drives metabolite clearance from the adult brain. science 342, 373–377 (2013).

    Article CAS PubMed Google Scholar 

  58. Hablitz, L. M. et al. Increased glymphatic influx is correlated with high EEG delta power and low heart rate in mice under anesthesia. Sci. Adv. 5, eaav5447 (2019).

    Article CAS PubMed PubMed Central Google Scholar 

  59. Osorio-Forero, A. et al. Noradrenergic circuit control of non-REM sleep substates. Curr. Biol. 31, 5009–5023 (2021).

    Article CAS PubMed Google Scholar 

  60. Antila, H. et al. A noradrenergic-hypothalamic neural substrate for stress-induced sleep disturbances. Proc. Natl. Acad. Sci. USA 119, e2123528119 (2022).

    Article CAS PubMed PubMed Central Google Scholar 

  61. Ringstad, G. et al. Brain-wide glymphatic enhancement and clearance in humans assessed with MRI. JCI insight 3, e121537 (2018).

    Article PubMed PubMed Central Google Scholar 

  62. Eide, P. K. et al. Clinical application of intrathecal gadobutrol for assessment of cerebrospinal fluid tracer clearance to blood. JCI insight 6, e147063 (2021).

    Article PubMed PubMed Central Google Scholar 

  63. Louveau, A. et al. Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. J. Clin. Investig. 127, 3210–3219 (2017).

    Article PubMed PubMed Central Google Scholar 

  64. Rasmussen, M. K., Mestre, H. & Nedergaard, M. Fluid transport in the brain. Physiol. Rev. 102, 1025–1151 (2022).

    Article CAS PubMed Google Scholar 

  65. Proulx, S. T. Cerebrospinal fluid outflow: a review of the historical and contemporary evidence for arachnoid villi, perineural routes, and dural lymphatics. Cell. Mol. Life Sci. 78, 2429–2457 (2021).

    Article CAS PubMed PubMed Central Google Scholar 

  66. van Osch, M. J. et al. Human brain clearance imaging: pathways taken by magnetic resonance imaging contrast agents after administration in cerebrospinal fluid and blood. NMR Biomed. 37, e5159 (2024).

    Article PubMed Google Scholar 

  67. Lau, K., Kotzur, R. & Richter, F. Blood–brain barrier alterations and their impact on Parkinson’s disease pathogenesis and therapy. Transl. Neurodegener. 13, 37 (2024).

    Article PubMed PubMed Central Google Scholar 

  68. Al-Bachari, S., Naish, J. H., Parker, G. J., Emsley, H. & Parkes, L. M. Blood-brain barrier leakage is increased in Parkinson’s disease. Front. Physiol. 11, 593026 (2020).

  69. Liu, X. et al. Hypercapnia exacerbates the blood–brain barrier disruption via promoting HIF-1a nuclear translocation in the astrocytes of the hippocampus: implication in further cognitive impairment in hypoxemic adult rats. Neurochem. Res. 45, 1674–1689 (2020).

    Article CAS PubMed PubMed Central Google Scholar 

  70. Zou, W. et al. Blocking meningeal lymphatic drainage aggravates Parkinson’s disease-like pathology in mice overexpressing mutated α-synuclein. Transl. Neurodegener. 8, 1–17 (2019).

    Article Google Scholar 

  71. Lee, H.-J., Bae, E.-J. & Lee, S.-J. Extracellular α-synuclein—a novel and crucial factor in Lewy body diseases. Nat. Rev. Neurol. 10, 92–98 (2014).

    Article CAS PubMed Google Scholar 

  72. Abeliovich, A. & Gitler, A. D. Defects in trafficking bridge Parkinson’s disease pathology and genetics. Nature 539, 207–216 (2016).

    Article PubMed Google Scholar 

  73. Coppens, S., Lehmann, S., Hopley, C. & Hirtz, C. Neurofilament-light, a promising biomarker: analytical, metrological and clinical challenges. Int. J. Mol. Sci. 24, 11624 (2023).

    Article CAS PubMed PubMed Central Google Scholar 

  74. Yang, Z. & Wang, K. K. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 38, 364–374 (2015).

    Article CAS PubMed PubMed Central Google Scholar 

  75. Ryman, S. G. et al. Cognition at each stage of lewy body disease with co-occurring Alzheimer’s disease pathology. J. Alzheimer’s Dis. 1, 14 (2021).

    Google Scholar 

  76. Irwin, D. J. et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 16, 55–65 (2017).

    Article PubMed PubMed Central Google Scholar 

  77. Jellinger, K. A., Seppi, K., Wenning, G. K. & Poewe, W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J. Neural Transm. 109, 329–339 (2002).

    Article CAS PubMed Google Scholar 

  78. Verbree, J. et al. Assessment of middle cerebral artery diameter during hypocapnia and hypercapnia in humans using ultra-high-field MRI. J. Appl. Physiol. 117, 1084–1089 (2014).

    Article PubMed Google Scholar 

  79. Slessarev, M. et al. Prospective targeting and control of end-tidal CO2 and O2 concentrations. J. Physiol. 581, 1207–1219 (2007).

    Article CAS PubMed PubMed Central Google Scholar 

  80. Fisher, J. A. The CO2 stimulus for cerebrovascular reactivity: fixing inspired concentrations vs. targeting end-tidal partial pressures. J. Cereb. Blood Flow. Metab. 36, 1004–1011 (2016).

    Article CAS PubMed PubMed Central Google Scholar 

  81. Liu, P., Jill, B. & Lu, H. Cerebrovascular reactivity (CVR) MRI with CO2 challenge: a technical review. Neuroimage 187, 104–115 (2019).

    Article PubMed Google Scholar

ziekte van Alzheimer, dementie, koolstofdioxide = CO2, zuurstofmasker, intermitterende hypercapnie, alfa-synucleïne, amyloïde bèta, gefosforyleerd tau, ziekte van Parkinson


Plaats een reactie ...

Reageer op "Korte pulsen van ingeademde koolstofdioxide = CO2 via een zuurstofmasker activeren het glymfatische systeem van de hersenen waardoor giftige eiwitten die verband houden met de ziekte van Alzheimer worden afgevoerd."


Gerelateerde artikelen
 

Gerelateerde artikelen

Korte pulsen van ingeademde >> Ultra sound dringt door de >> Luchtvervuiling zoals fijnstof, >> Alzheimer - dementie is via >> DunedinPACE hersenscan meet >> Eiwit TDP-43 lijkt belangrijke >> Alzheimer - dementie is negen >> Bloedtest APS2 zou de vroege >> Minder buikvet en meer spiermassa >> Artikelen over ziekte van >>